Jason Fontenot
Chief Scientific Officer Stylus Medicine
Dr. Fontenot is Chief Scientific Officer at Stylus Medicine. Previously, he served as CSO at Sangamo Therapeutics, CSO at Immusoft, Head of Exploratory Research at Juno Therapeutics, and Group Leader in Immunology Research at Biogen. With deep expertise in immunology, genome engineering, CAR T-cell therapy, and immune-mediated disease—and a track record of translating cutting-edge science into medicines—Dr. Fontenot is a recognized strategic thinker and leader in gene and cell therapy.
Seminars
As in vivo cell and gene therapies moves into the clinic worldwide, diverse regulatory pathways across Asia are shaping how quickly first patients are dosed. This workshop examines the role of Asia with a focus on China’s investigator-initiated trials and what global sponsors can responsibly learn from them.
This workshop will:
- Cover essential elements of study design, CMC planning, safety monitoring, ethics, and data quality
- Explain how to effectively bridge investigator-initiated trials into registrational pathways
- Provide clear decision criteria and practical guidance on when to leverage Asian clinical evidence
- Share collaboration models and a practical playbook for integrating Asian data into global development plans
- Distilling the past year’s clinical and translational progress into portfolio-relevant proof points, sharpening investment, and resource allocation
- Prioritizing indications and modalities where in vivo approaches add differentiated value alongside existing assets, focusing pipeline sequencing
- Aligning global development routes, data portability, and CMC readiness with near-term regulatory and commercial realities, accelerating time to value
